Morgan Stanley raised Pfizer Inc.(PFE:NYE) to $48 from $45

STA Research
by: STA Research

Morgan Stanley maintained Pfizer Inc. with a Equal-Weight rating, and raised the target to $48 from $45.

Our view of the stock is Neutral with a score of 5 out of 10, where 0 is very bearish and 10 very bullish.

What to like:

High market capitalization This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable. Superior total returns The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. Underpriced compared to earnings The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason. Underpriced compared to book value The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason. Low debt The company is less leveraged than its peers,  and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential. Positive cash flow The company had positive total cash flow in the most recent four quarters. Positive free cash flow The company had positive total free cash flow in the most recent four quarters. Underpriced on free cash flow basis The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:

Poor risk adjusted returns This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution. Below median dividend returns The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income. Overpriced on cash flow basis The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy. Poor return on equity The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers. Poor capital utilization The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers. Poor return on assets The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers. Low Revenue Growth. Low Dividend Growth This stock has shown below median dividend growth in the previous 5 years compared to its sector.

 

Stock Target Advisor is not a broker/dealer, investment advisor or a platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information and education in order to help investors with their own research. No content in our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter in any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published. Required fields are marked *